WO2008156330A1 - Utilisation de xanthorrhizol pour traitement anti-rides - Google Patents

Utilisation de xanthorrhizol pour traitement anti-rides Download PDF

Info

Publication number
WO2008156330A1
WO2008156330A1 PCT/KR2008/003522 KR2008003522W WO2008156330A1 WO 2008156330 A1 WO2008156330 A1 WO 2008156330A1 KR 2008003522 W KR2008003522 W KR 2008003522W WO 2008156330 A1 WO2008156330 A1 WO 2008156330A1
Authority
WO
WIPO (PCT)
Prior art keywords
xanthorrhizol
extract
curcuma xanthorrhiza
collagen
wrinkle
Prior art date
Application number
PCT/KR2008/003522
Other languages
English (en)
Inventor
Jae-Kwan Hwang
Jae-Seok Shim
Hae Ji Lee
Yu-Mi Cho
Song Hui Gwon
Original Assignee
Biocare Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocare Co., Ltd. filed Critical Biocare Co., Ltd.
Priority to JP2010513123A priority Critical patent/JP2010530412A/ja
Publication of WO2008156330A1 publication Critical patent/WO2008156330A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/347—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9794—Liliopsida [monocotyledons]

Definitions

  • the present invention relates to novel use of an extract of Curcuma xanthorrhiza and xanthorrhizol, and more particularly, the present invention relates to a novel anti-wrinkle composition comprising an extract of Curcuma xanthorrhiza or a compound represented by Formula 1 as an effective component, novel use of the said extract or the compounds for reducing wrinkle, inducing collagen synthesis or suppressing collagen degradation, and novel method of the said extract or the compounds for reducing wrinkle, inducing collagen synthesis or suppressing collagen degradation.
  • wrinkles are a natural part of aging, which is caused by repeated muscular contractions for a long period of time.
  • Skin aging is broadly classified into intrinsic aging and extrinsic aging.
  • the intrinsic aging is difficult to regulate, because it is caused by genetic factors, but extrinsic aging is easy to regulate artificially, because it is caused by environmental factors.
  • studies on the prevention of extrinsic aging have been continued, and particularly, studies on the prevention of wrinkle formation resulting from extrinsic photoaging, which progresses due to long-term exposure to UV radiation, have received attention (Gilchre st B. A., J. Am. Acad. Dermatol., 1989:21:610- 613) .
  • MMP-I- is an enzyme involved in the degradation of the extracellular matrix and the basement membrane, and it has been reported that the activity of matrix metalloproteinase-1 in the skin is increased due to UV radiation to remarkably degrade collagen, and thus matrix metalloproteinase-1 has an important effect on collagen degradation and plays a very important role in wrinkle formation (Sim G. S., Kim J. H et al., Kor. J. Biotechnol. Bioeng., 2005 : 20 (1) : 40-45) .
  • retinoid is used as a means for solving photoaging phenomena, such as wrinkles resulting from sunlight, skin thickening, skin drooping and a decrease in skin elasticity.
  • retinoid has a problem in that it is a very unstable compound, which is sensitive to UV light, moisture, heat and oxygen such that a chemical change therein easily occurs.
  • the present invention provides an anti-wrinkle composition
  • xanthorrhizol which is represented by Formula 1 as an effective component.
  • the present invention provides a use of xanthorrhizol, which is represented by Formula 1 for the manufacture of an agent for reducing wrinkle, inducing collagen synthesis or suppressing collagen degradation.
  • the present invention provides a method comprising administering or applying an effective amount of xanthorrhizol, which is represented by Formula 1 for reducing wrinkle, inducing collagen synthesis or suppressing collagen degradation.
  • the present invention provides an anti-wrinkle composition comprising an extract of Curcuma xanthorrhiza as an effective component.
  • the present invention provides a use of an extract of Curcuma xanthorrhiza for the manufacture of an agent for reducing wrinkle, inducing collagen synthesis or suppressing collagen degradation.
  • the present invention provides a method comprising administering or applying an effective amount of an extract of Curcuma xanthorrhiza for reducing wrinkle, inducing collagen synthesis or suppressing collagen degradation to a subject in need thereof.
  • the present invention provides novel use of xanthorrhizol isolated and purified from Curcuma xanthorrhiza.
  • Curcuma xanthorrhiza is a Zingiberaceae plant which is a traditional medicinal herb, commonly known as temu lawak or Javanese turmeric in Indonesia, and includes terpenoid-based compounds, such as artumenone, ⁇ - curcumene, ⁇ -curcumene, curzerenone, germacrone, ⁇ - sesquiphellandrene, ⁇ -turmerone, ⁇ -turmerone, xanthorrhizol, etc., 7-30% essential oil, 30-40% carbohydrates, and 0.02-2.0% aromatic pigments such as curcuminoid, etc. (Lin S. C. et al . , Am. J. Chin. Med., 1995:23:243-254).
  • Xanthorrhizol is a kind of sesquiterpene, which is a typical component found in Curcuma xanthorrhiza.
  • Xanthorrhizol is known to have an antibacterial effect against oral microorganisms (Hwang, J. K. et al., Fitorick, 2000:71:321-323; Hwang, J. K. et al., Planta Medica, 2000:66:196-197), an activity to inhibit toxicity caused by anticancer drugs (Kim, S. H. et al., Toxicology and Applied Pharmacology, 2004:196:346-355; Kim, S. H.
  • methods for extracting Curcuma xanthorrhiza include an organic solvent extraction method, a supercritical fluid extraction method, a microwave extraction method and an ultrasonic extraction method.
  • a process of isolating and purifying xanthorrhizol from Curcuma xanthorrhiza is disclosed in Korean Patent Laid- Open Publication No. 2000-0073295.
  • xanthorrhizol of the present invention can be isolated and purified using a conventional extraction and separation method.
  • an extract of Curcuma xanthorrhiza is purified by using one selected from the group of consisting of water, Cl-C ⁇ organic alcohols such as methanol, ethanol, propanol, isopropanol, butanol, acetone, ether, chloroform, ethyl acetate, methylene chloride, hexane, cyclohexane, petroleum ether, diethylether, and benzene alone or in a mixture thereof.
  • Cl-C ⁇ organic alcohols such as methanol, ethanol, propanol, isopropanol, butanol, acetone, ether, chloroform, ethyl acetate, methylene chloride, hexane, cyclohexane, petroleum ether, diethylether, and benzene alone or in a mixture thereof.
  • a solvent may be added to Curcuma xanthorrhiza powder in an amount 1-20 times the weight of the powder.
  • a solvent may be added to Curcuma xanthorrhiza powder in an amount 2-5 times the weight of the powder in order to increase extraction efficiency.
  • the extraction ⁇ process is preferably carried out at room temperature under atmospheric pressure, and the extraction is carried out for 6-96 hours, and preferably 36-72 hours, even though it varies depending on the extraction temperature. Also, in the extraction process, a shaker may be used to further increase extraction efficiency.
  • Curcuma xanthorrhiza Before use in the extraction process, Curcuma xanthorrhiza may be washed after being harvested or dried after being washed. The drying process may be carried out using any one of sun-drying, shade-drying, hot-air drying and natural drying. Also, to increase extraction efficiency, Curcuma xanthorrhiza or dried Curcuma xanthorrhiza may be used after it is ground with a grinder.
  • xanthorrhizol can be separated by obtaining a fraction according to the migration distance of a solvent using TLC (thin-layer chromatography) , particularly, a TLC method which uses a mixed solvent of hexane and ethylacetate (10:1), and acetylating and deacetylating the separated fraction.
  • TLC thin-layer chromatography
  • xanthorrhizol in a preferred embodiment, dried Curcuma xanthorrhiza is ground to a size of 20-40 mesh, and then 100 g of the ground Curcuma xanthorrhiza is mixed with 400 ml of 75 vol% methanol and extracted repeatedly at room temperature for 2 days. The extracted sample was filtered through Whatman filter paper No. 2 to obtain a crude extract. The 75% methanol crude extract thus obtained was mixed with each of ethylacetate and butanol at a ratio of 1:1 to extract a component soluble in each of the solvents, and finally a water-soluble component was obtained from the extract. The resulting material was extracted twice with each solvent, and then only each solvent layer was separated therefrom.
  • the solvent component was evaporated, thus preparing a methanol fraction, an ethylacetate fraction, a butanol fraction and a water fraction.
  • the ethylacetate fraction was developed by TLC with a mixed solvent of hexane and ethylacetate (10:1 (v/v) ) , and the resulting fraction was subjected to acetylation and deacetylation, thus obtaining xanthorrhizol.
  • the above-described inventive Curcuma xanthorrhiza extract and xanthorrhizol inhibit the production of matrix metalloproteinase-1 (MMP-I) in human skin fibroblasts, caused by UV radiation with concentration- dependent manner, and increase the synthesis of type-1 procollagen.
  • MMP-I matrix metalloproteinase-1
  • hairless mice radiated with UV light was treated with the Curcuma xanthorrhiza extract and xanthorrhizol, the synthesis of collagen in the mice was increased.
  • the Curcuma xanthorrhiza extract and xanthorrhizol according to the present invention have very excellent effects of inhibiting the production of matrix metalloproteinase-1 (MMP-I) , caused by UV radiation, and synthesizing collagen.
  • MMP-I matrix metalloproteinase-1
  • the present invention provides an anti-wrinkle composition
  • an anti-wrinkle composition comprising an extract of Curcuma xanthorrhiza or xanthorrhizol as an effective component.
  • the said composition may be the composition for cosmetics or food.
  • composition for cosmetics may be prepared by well known skills in the art including one or more conventional excipient and additives as well as an extract of Curcuma xanthorrhiza or xanthorrhizol. More particularly, a composition for cosmetics of the present invention contains an extract of Curcuma xanthorrhiza or xanthorrhizol as an effective component, and may be prepared in the form of basic cosmetics (lotions, cream, essence, cleansers such as cleansing foam and cleansing water, pack, body oil, massage cream), coloring cosmetics (foundation, lip-stick, mascara, make-up base), hair care composition (shampoo, rinse, hair conditioner, hair gel) with dermatologically acceptable excipients.
  • basic cosmetics such as cleansing foam and cleansing water, pack, body oil, massage cream
  • coloring cosmetics foundation, lip-stick, mascara, make-up base
  • hair care composition shampoo, rinse, hair conditioner, hair gel
  • the said excipients may comprise, but not limited thereto, skin softener, skin infiltration enhancer, colorant, odorant, emulsifier, thickener, or solvent.
  • a cleanser and soap comprising an extract of Curcuma xanthorrhiza or xanthorrhizol
  • they may be prepared easily by adding an extract of Curcuma xanthorrhiza or xanthorrhizol to conventional cleanser or soap base.
  • a cream it may be prepared by adding an extract of Curcuma xanthorrhiza or xanthorrhizol to conventional oil-in-water cream base.
  • an extract of Curcuma xanthorrhiza or xanthorrhizol of the present invention may be properly combined by the form of composition for cosmetics in the range of 0.005-10 wt%, and preferably 0.01-5 wt%, based on the total weight of a formulation.
  • composition is added in an amount of less than 0.005 wt%, it will provide low effect in reducing wrinkle, and if it is added in an amount of more than 10 wt%, it will show no significant difference in reducing wrinkle while increasing only their addition amount.
  • composition for food of the present invention may comprise all kind of form including functional food, nutritional supplement, health food, and food additives.
  • Said food composition may be prepared as various forms by the conventional method known in the art .
  • an extract of Curcuma xanthorrhiza or xanthorrhizol of the present invention may be prepared into tea, juice, and drink for drinking or may be prepared into granules, capsules, or power for uptake.
  • conventional active ingredient which is well known as having activity in reducing and preventing wrinkle may be mixed with an extract of Curcuma xanthorrhiza or xanthorrhizol of the present invention so as to prepare a composition.
  • an extract of Curcuma xanthorrhiza or xanthorrhizol of the present invention may be added to fruits, and their processed foods (e.g. canned fruit, bottled fruit, jam, marmalade etc.), fishes, meats, and their processed foods (e.g. ham, sausage, corn beef etc.), breads and noodles (e.g. Japanese noodle, buckwheat noodle, Chinese noodle, spaghetti, macaroni etc.), fruit juice, drinks, cookies, toffee, dairy products (e . g. butter, cheese etc.), vegetable oil, margarine, vegetable protein, retort food, frozen food, various seasonings (e.g. soybean paste, soybean sauce, sauce etc.) so as to prepare a composition.
  • fruits, and their processed foods e.g. canned fruit, bottled fruit, jam, marmalade etc.
  • fishes, meats, and their processed foods e.g. ham, sausage, corn beef etc.
  • an extract of Curcuma xanthorrhiza or xanthorrhizol of the present invention may be prepared in a form of powder or extract for food additives.
  • An extract of Curcuma xanthorrhiza or xanthorrhizol of the present invention may be properly combined by the form of composition for food preferably in the range of 0.0001 to 50 wt% based on the total weight of a food.
  • the present invention provides a use of an extract of Curcuma xanthorrhiza or xanthorrhizol for preparing an agent for reducing wrinkle. Also, it provides a use of an extract of Curcuma xanthorrhiza or xanthorrhizol for preparing an agent for inducing collagen synthesis or suppressing collagen degradation. In addition, the present invention provides a method comprising administering or applying an effective amount of an extract of Curcuma xanthorrhiza to an subject in need thereof for reducing wrinkle. Also, it provides a method comprising administering or applying an effective amount of an extract of Curcuma xanthorrhiza or xanthorrhizol inducing collagen synthesis or suppressing collagen degradation to a subject in need thereof.
  • the "effective amount” refers to the amount effective in reducing wrinkle, inducing collagen synthesis or suppressing collagen degradation in the subject for administration and the "subject” refers to mammals, particularly, animals comprising human. The subject may be patient in need of treatment.
  • An extract of Curcuma xanthorrhiza or xanthorrhizol of the present invention may be administered until desired effect among the said effects are derived, and can be administered by oral or parenteral ways which are well known in the art.
  • an extract of Curcuma xanthorrhiza or xanthorrhizol of the present invention suppresses collagen degradation enzyme-1 (MMP-I, matrix metalloproteinase-1) which is important in wrinkle formation and thereby suppresses collagen degradation and activated formation of new collagen (type-1 procollagen), and have improved effect on reducing wrinkle caused by photoaging. Accordingly, an extract of Curcuma xanthorrhiza or xanthorrhizol of the present invention may be useful for preventing or treating wrinkle caused by photoaging.
  • MMP-I matrix metalloproteinase-1
  • FIG. 1 is a graph showing suppress activity of collagen degradation enzyme-1 by an extract of Curcuma xanthorrhiza .
  • FIG. 2 is a graph showing activity of formation of collagen by an extract of Curcuma xanthorrhiza .
  • FIG. 3 is a graph showing suppress activity of collagen degradation enzyme-1 by xanthorrhizol.
  • FIG. 4 is a graph showing activity of formation of collagen by xanthorrhizol.
  • Example 1 Cell proliferation effect
  • an MTT assay (3- (4 , 5-dimethylthiazol-2-yl) -2, 5-diphenyl tetrazolium bromide reduction method) was carried out using fibroblasts.
  • human normal fibroblasts were plated into a 96-well plate at a concentration of 2 x 10 5 cells/well and primarily cultured in 10% FBS (fetal bovine serum) - containing DMEM medium in conditions of 37 ° C and 5% CO 2 for 24 hours.
  • FBS fetal bovine serum
  • the cells were treated with varying concentrations of the inventive sample.
  • the medium was replaced with a serum-free medium, and the cells were secondarily cultured for 48 hours.
  • 100 ⁇ i of MTT solution was added to the medium.
  • the resulting solution was left to stand for 4 hours, and then the medium was removed.
  • 100 ⁇ Jt of dimethyl sulfoxide solution was added to each well and stirred for 20 minutes, and then the absorbance of each well at 540 nm was measured with a microplate reader.
  • Test Example 1 Cell proliferation effects of Curcuma xanthorrhiza extract and xanthorrhizol According to the method of Example 1, the cell proliferation effects of Curcuma xanthorrhiza extract and xanthorrhizol were measured. In the MTT assay, a culture medium not treated with the sample was used as a control group and measured for absorbance, and green tea extract and epigallocatechin-3-gallate (EGCG) , known to have the effect of reducing skin wrinkles, were used as comparative groups. The analysis results are shown in Table 1 below. [Table 1]
  • the Curcuma xanthorrhiza extract and xanthorrhizol of the present invention had excellent cell proliferation effects compared to those of the comparative groups.
  • Example 2 Measurement of matrix metalloproteinase-1 (MMP-I) and collagen biosynthesis in fibroblasts radiated with UV light
  • Fibroblasts were cultured in a 60-mm dish at a concentration of 2 x 10 5 cells/ml to a confluence of about 85%. Before UV radiation, the medium was removed, and the cells were washed with PBS to remove a serum component therefrom, and then radiated with UV light at a dose of 20 mJ/cm 2 . After the fibroblast cells were radiated with UV light, the cells were treated with each of the samples and cultured for 48 hours. Then, the culture medium was measured for the expression levels of matrix metalloproteinase-1 (MMP-I) and collagen.
  • MMP-I matrix metalloproteinase-1
  • MMP-I matrix metalloproteinase-1
  • collagen Western blot was used, and the amount of total protein in the medium containing the fibroblasts cultured therein was quantified using the Bradford method.
  • the extracted protein was electrophoresed on 10% SDS- polyacrylamide gel, and then transferred to a nitrocellulose membrane.
  • the membrane was blocked with 5% skim milk at room temperature for 1 hour in order to prevent it from being contaminated with other unknown proteins.
  • Each of primary antibodies to matrix metalloproteinase-1 and type-1 procollagen was diluted in a blocking solution at a ratio of 1:1000 and allowed to react with the membrane at room temperature for 2 hours. After the primary antibody reaction, the membrane was washed three times with Tris-buffer saline Tween 20 (TBST) with shaking for 10 minutes each time.
  • TST Tris-buffer saline Tween 20
  • Each of secondary antibodies recognizing the primary antibodies to matrix metalloproteinase-1 and type-1 procollagen was diluted in 5% skim milk at a ratio of 1:1000 and allowed to react with the membrane at room temperature for 1 hour. Then, the membrane was washed three times with tris- buffer saline Tween 20 with shaking for 10 minutes each time in the same manner as in the case of the primary antibody reaction, and then was developed by chemiluminescence .
  • Test Example 2 Measurement of expression levels of matrix metalloproteinase-1 (MMP-I) and collagen in cells when treated with Curcuma xanthorrhiza ethanol extract
  • Test Example 3 Measurement of expression levels of matrix metalloproteinase-1 (MMP-I) and collagen in cells when treated with Curcuma xanthorrhiza hexane extract
  • matrix metalloproteinase-1 was inhibited by 75% at 0.5 //g/ml of the Curcuma xanthorrhiza hexane extract, and collagen synthesis was increased by 191% at
  • Test Example 4 Measurement of expression levels of matrix metalloproteinase-1 (MMP-I) and collagen in cells when treated with xanthorrhizol
  • the cells were treated with xanthorrhizol, xanthorrhizol showed matrix metalloproteinase-1 inhibitory activities of 18% at 0.001 ⁇ M, 68% at 0.01 ⁇ M and 92% at 0.1 ⁇ M.
  • the comparative group EGCG showed a matrix metalloproteinase-1 inhibitory activity of 72%, suggesting that treatment with xanthorrhizol had higher activity.
  • FIG. 4 when the cells were treated with xanthorrhizol, xanthorrhizol showed collagen synthesis-promoting effects of 57% at 0.01 ⁇ M and 86% at 0.1 ⁇ M.
  • xanthorrhizol according to the present invention has activity higher than that of EGCG, well known to be effective in reducing wrinkles.
  • Examples 3 to 6 Preparation of lotions containing Curcuma xanthorrhiza extract Curcuma xanthorrhiza ethanol extract was used to prepare lotions having compositions of Examples 3 to 6. The extract was dissolved in ethanol at concentrations of 10.0 wt%, 1.0 wt%, 0.1 wt% and 0.01 wt%, and the weight thereof was adjusted with ethanol. Then, the solution was uniformly stirred.
  • Curcuma xanthorrhiza ethanol extract was used to prepare creams having compositions of Examples 7 to 10.
  • materials (I)- (5) in Table 3 were dissolved at 75- 80 ° C , and materials (6) -(9) were dissolved at the same temperature.
  • the materials (6) -(9) were emulsified in the materials (I)- (5), and then the crude extract was added thereto at each of concentrations of 10.0 wt%, 1.0 wt%, 0.1 wt% and 0.01%, and the emulsions were stirred.
  • fragrance was added thereto and the balance of purified water was added.
  • Xanthorrhizol was used to prepare lotions having compositions of Examples 11 to 14.
  • Xanthorrhizol was dissolved in water at concentrations of 5.0 wt%, 0.1 wt%, 0.01 wt% and 0.001 wt%, and the mix with phosphoric acid solution. Then, the mixture of ethanol, glycerin, propyleneglycol is admixed with the said solution, and fragrance, preservatives are added and adjusted with water, and the solution was uniformly stirred.
  • Purified water Purified water: Purified water: Purified water: balance balance balance balance balance
  • Examples 15 to 18 Preparation of creams containing xanthorrhizol xanthorrhizol was used to prepare creams having compositions of Examples 15 to 18. First, materials (I)-
  • Test Example 5 In vivo measurement of collagen synthesis of Curcuma xanthorrhiza extract-containing composition
  • mice were radiated with UV light at a dose of 20 mJ/cm 2 one time everyday for 4 weeks, and then 100 ml of each of the Curcuma xanthorrhiza ethanol extract- containing compositions of Examples 3 to 10 was applied to the back of the mice. Then, the mice were biopsied, and the formation of collagen in the biopsied tissue was histologically measured. Herein, the measurement of the amount of newly produced collagen was carried out by immunostaining the tissue and subjecting the immunostained tissue to image analysis. The measurement results are shown in Table 6 below. [Table 6]
  • Test Example 6 In vivo measurement of collagen synthesis of xanthorrhizol-containing composition
  • mice were radiated with UV light at a dose of 20 mJ/cm 2 one time everyday for 4 weeks, and then 100 ml of each of the xanthorrhizol-containing compositions of Examples 11 to 18 was applied to the back of the mice. Then, the mice were biopsied, and the formation of collagen in the biopsied tissue was histologically measured.
  • the measurement of the amount of newly produced collagen was carried out by immunostaining the tissue and subjecting the immunostained tissue to image analysis. The measurement results are shown in Table 7 below.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Cette invention concerne une nouvelle utilisation d'un extrait de Curcuma xanthorrhiza ou de xanthorrhizol isolé à partir de l'extrait et représenté par la formule 1. L'extrait de Curcuma xanthorrhiza et de xanthorrhizol décrits dans cette invention sont actifs pour supprimer l'enzyme -1de dégradation du collagène (MMP1, métalloprotéinase matricielle-1) et pour former un nouveau collagène (procollagène de type-1) car ils ont un effet permettant d'empêcher les rides. Ainsi, un extrait de Curcuma xanthorrhiza ou de xanthorrhizol peut être utilisé pour prévenir ou traiter des rides provoquées par le photovieillissement.
PCT/KR2008/003522 2007-06-20 2008-06-20 Utilisation de xanthorrhizol pour traitement anti-rides WO2008156330A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2010513123A JP2010530412A (ja) 2007-06-20 2008-06-20 皮膚皺改善用キサントリゾールの使用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2007-0060177 2007-06-20
KR1020070060177A KR101416993B1 (ko) 2007-06-20 2007-06-20 주름개선용 화장료 조성물

Publications (1)

Publication Number Publication Date
WO2008156330A1 true WO2008156330A1 (fr) 2008-12-24

Family

ID=40156407

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2008/003522 WO2008156330A1 (fr) 2007-06-20 2008-06-20 Utilisation de xanthorrhizol pour traitement anti-rides

Country Status (3)

Country Link
JP (1) JP2010530412A (fr)
KR (1) KR101416993B1 (fr)
WO (1) WO2008156330A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013014579A (ja) * 2011-06-09 2013-01-24 Kao Corp Ｔｒｐｖ３活性化剤
FR3005830A1 (fr) * 2013-05-24 2014-11-28 Distrib Et De Prestation De Services Sdp Soc D Composition comportant au moins une substance active issue du vegetal

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101309335B1 (ko) * 2010-06-30 2013-09-16 (주)아모레퍼시픽 콜라겐 조절용 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030069391A (ko) * 2002-02-20 2003-08-27 주식회사 엘지생활건강 천연 항균제를 함유한 체취 억제용 화장료 조성물
US6696404B1 (en) * 1999-05-08 2004-02-24 Lg Household & Healthcare Antibacterial composition having xanthorrizol
US20040266634A1 (en) * 2001-12-18 2004-12-30 Dirk Bockmuhl Adhesion inhibition of moulds
US20050191267A1 (en) * 2004-02-04 2005-09-01 Omboon Luanratana Anti-photoaging cosmeceutical composition

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004002267A (ja) * 2002-03-28 2004-01-08 Kobayashi Pharmaceut Co Ltd コラゲナーゼ阻害剤及びその利用
JP2004075632A (ja) * 2002-08-21 2004-03-11 Noevir Co Ltd 真皮線維芽細胞賦活剤
US7514092B2 (en) * 2004-12-22 2009-04-07 Avon Products, Inc. Compositions and methods of their use for improving the condition and appearance of skin

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696404B1 (en) * 1999-05-08 2004-02-24 Lg Household & Healthcare Antibacterial composition having xanthorrizol
US20040266634A1 (en) * 2001-12-18 2004-12-30 Dirk Bockmuhl Adhesion inhibition of moulds
KR20030069391A (ko) * 2002-02-20 2003-08-27 주식회사 엘지생활건강 천연 항균제를 함유한 체취 억제용 화장료 조성물
US20050191267A1 (en) * 2004-02-04 2005-09-01 Omboon Luanratana Anti-photoaging cosmeceutical composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHEAH Y.H. ET AL.: "Xanthorrhizol exhibits antiproliferative activity on MCF-7 breast cancer cells via apoptosis induction", ANTICANCER RES., vol. 26, no. 6B, 2006, pages 4527 - 4534 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013014579A (ja) * 2011-06-09 2013-01-24 Kao Corp Ｔｒｐｖ３活性化剤
FR3005830A1 (fr) * 2013-05-24 2014-11-28 Distrib Et De Prestation De Services Sdp Soc D Composition comportant au moins une substance active issue du vegetal

Also Published As

Publication number Publication date
KR101416993B1 (ko) 2014-07-08
JP2010530412A (ja) 2010-09-09
KR20080111790A (ko) 2008-12-24

Similar Documents

Publication Publication Date Title
JP6196346B2 (ja) リグナン系化合物の皺改善用途
Sari et al. Antioxidant and tyrosinase inhibitor activities of ethanol extracts of brown seaweed (Turbinaria conoides) as lightening ingredient
KR101957847B1 (ko) 흑노호 추출물을 포함하는 피부 미백용 조성물
KR101787074B1 (ko) 천연물 복합 추출물을 포함하는 피부 미백 및 피부 주름 개선용 화장료 조성물
EP2200574B1 (fr) Utilisation nouvelle de dérivés de panduratine ou d'un extrait de kaempferia pandurata en contenant
KR20190063549A (ko) 대나무 발효물을 함유하는 화장료 조성물
KR20080049332A (ko) 미백용 합마유 추출물
KR20200064240A (ko) 초임계 유체 추출법을 이용한 괭생이모자반 추출물을 함유하는 항산화 또는 피부미백 화장료 조성물
KR102544792B1 (ko) 락토바실러스 브레비스 균주로 발효한 해조류 복합 발효 추출물을 유효성분으로 포함하는 피부 탄력 또는 피부 주름 개선, 항산화 및 피부 보습용 조성물
KR101864223B1 (ko) 삼붕냐와 추출물을 함유하는 화장료 조성물
WO2008156330A1 (fr) Utilisation de xanthorrhizol pour traitement anti-rides
JP2008013481A (ja) ゲットウ（Ａｌｐｉｎｉａｓｐｅｃｉｏｓａ）由来のチロシナーゼ活性阻害剤及びリポキシゲナーゼ活性阻害剤
KR101904501B1 (ko) 퓨코스테롤을 유효성분으로 포함하는 피부주름 개선 또는 피부탄력 증진용 화장료 조성물
KR20090097550A (ko) 슈잔드린 및 이 추출물을 유효성분으로 함유하는 화장료조성물
KR101050484B1 (ko) 락톤계 화합물을 유효성분으로 함유하는 피부 미백용 조성물
KR102331119B1 (ko) 흑미 추출물의 발효물 및 땅콩 새싹 추출물의 발효물을 포함하는 피부 노화 예방용 조성물
KR101618595B1 (ko) 토마티딘을 함유하는 미숙 토마토 분해물 제조 방법 및 이를 함유하는 화장료 조성물
KR101525090B1 (ko) 피부미백용 화장료 조성물
JP2011032177A (ja) Ｋｉｔ切断抑制剤
KR102326086B1 (ko) 닥나무 복합 추출물을 유효성분으로 포함하는 피부 미백, 주름개선, 보습, 및 피부장벽 강화용 조성물
KR20160149499A (ko) 와송에서 추출한 단백질 분획물을 유효성분으로 포함하는 항산화제 및 화장료 조성물
KR20210047588A (ko) 큰도꼬마리 추출물을 이용한 피부 미백용 조성물
KR20200038114A (ko) 분갈 추출물 또는 이로부터 유래된 화합물을 포함하는 피부 개선용 조성물
KR102575303B1 (ko) 식물 복합추출물을 유효성분으로 포함하는 콜라겐 합성 촉진용 조성물
KR101551240B1 (ko) 검은 생강 추출물을 포함하는 피부미백용 화장료 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08766481

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2010513123

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC, FORM 1205A DATED 01.04.2010

122 Ep: pct application non-entry in european phase

Ref document number: 08766481

Country of ref document: EP

Kind code of ref document: A1